Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Accumulated Expenses (2020 - 2022)

Historic Accumulated Expenses for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to $13.8 million.

  • Atea Pharmaceuticals' Accumulated Expenses fell 7104.78% to $13.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was $13.8 million, marking a year-over-year decrease of 7104.78%. This contributed to the annual value of $52.2 million for FY2021, which is 26297.33% up from last year.
  • Atea Pharmaceuticals' Accumulated Expenses amounted to $13.8 million in Q3 2022, which was down 7104.78% from $10.5 million recorded in Q2 2022.
  • Atea Pharmaceuticals' Accumulated Expenses' 5-year high stood at $52.2 million during Q4 2021, with a 5-year trough of $6.3 million in Q3 2020.
  • In the last 3 years, Atea Pharmaceuticals' Accumulated Expenses had a median value of $15.1 million in 2021 and averaged $24.7 million.
  • Per our database at Business Quant, Atea Pharmaceuticals' Accumulated Expenses skyrocketed by 65208.2% in 2021 and then tumbled by 7236.11% in 2022.
  • Over the past 3 years, Atea Pharmaceuticals' Accumulated Expenses (Quarter) stood at $14.4 million in 2020, then surged by 262.97% to $52.2 million in 2021, then tumbled by 73.53% to $13.8 million in 2022.
  • Its last three reported values are $13.8 million in Q3 2022, $10.5 million for Q2 2022, and $24.8 million during Q1 2022.